quantisnow
FeedTopReportsPricing
⌘K
Live feed
10:16:00·87d
PRRelease
Ardelyx Inc. logo
Fate Therapeutics Inc. logo
MannKind Corporation logo
+1

Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets

ARDX· Ardelyx Inc.FATE· Fate Therapeutics Inc.MNKD· MannKind CorporationVRTX· Vertex Pharmaceuticals Incorporated
Health Care
Original source

Companies

  • ARDX
    Ardelyx Inc.
    Health Care
  • FATE
    Fate Therapeutics Inc.
    Health Care
  • MNKD
    MannKind Corporation
    Health Care
  • VRTX
    Vertex Pharmaceuticals Incorporated
    Health Care

Recent analyst ratings

  • Mar 18VRTXUpdateMaxim Group$575.00
  • Mar 10VRTXUpdateJefferies$580.00
  • Mar 10VRTXUpdateOppenheimer$600.00
  • Feb 27MNKDUpdateRBC Capital Mkts$3.50
  • Feb 13VRTXUpdateOppenheimer$540.00
  • Jan 28VRTXUpdateBarclays$606.00

Related

  • INSIDER3h
    Amendment: SEC Form 4 filed by Director Redmile Group, Llc
  • PR16h
    Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026
  • INSIDER1d
    SEC Form 4 filed by Redmile Group, Llc
  • SEC1d
    Amendment: SEC Form SCHEDULE 13D/A filed by Fate Therapeutics Inc.
  • INSIDER1d
    SEC Form 3 filed by new insider Ettenberg Felecia
  • PR3d
    Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer
  • INSIDER6d
    SEC Form 4 filed by Upadhyay Suketu
  • INSIDER6d
    SEC Form 4 filed by Sachs Bruce I
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022